<DOC>
	<DOC>NCT00407212</DOC>
	<brief_summary>This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents</brief_summary>
	<brief_title>A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy</brief_title>
	<detailed_description>This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male or female ,aged 3080 years Clinical diagnosis of early stage idiopathic Parkinson's disease Experiencing two of the three following signs; bradykinesia, rigidity, and tremor Not currently taking any antiparkinson medication A history of alcohol or drug abuse in the past year A diagnosis psychiatric illness Patients who currently are taking MAO inhibitors within 30 days of entering the study Patients who are hypersensitive to selegiline, MAOB inhibitors, or tricyclic antidepressants Additional inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>early stage idiopathic Parkinson's disease</keyword>
</DOC>